Pfizer Price to Sales Ratio 2010-2024 | PFE

Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of November 20, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Pfizer P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-11-19 25.10 2.41
2024-09-30 28.49 $10.41 2.74
2024-06-30 27.18 $9.70 2.80
2024-03-31 26.56 $9.64 2.75
2023-12-31 27.14 $10.26 2.64
2023-09-30 30.84 $12.13 2.54
2023-06-30 33.72 $13.70 2.46
2023-03-31 37.10 $16.28 2.28
2022-12-31 46.17 $17.51 2.64
2022-09-30 39.09 $17.45 2.24
2022-06-30 46.47 $17.69 2.63
2022-03-31 45.53 $16.16 2.82
2021-12-31 51.54 $14.27 3.61
2021-09-30 37.21 $12.12 3.07
2021-06-30 33.57 $9.75 3.45
2021-03-31 30.76 $8.17 3.76
2020-12-31 30.91 $7.41 4.17
2020-09-30 28.92 $5.70 5.07
2020-06-30 25.52 $6.12 4.17
2020-03-31 25.21 $6.70 3.76
2019-12-31 29.96 $7.19 4.17
2019-09-30 27.21 $7.06 3.86
2019-06-30 32.50 $7.03 4.62
2019-03-31 31.58 $6.96 4.54
2018-12-31 32.19 $6.81 4.73
2018-09-30 32.25 $8.88 3.63
2018-06-30 26.32 $8.83 2.98
2018-03-31 25.50 $8.71 2.93
2017-12-31 25.79 $8.79 2.93
2017-09-30 25.19 $8.65 2.91
2017-06-30 23.47 $8.61 2.73
2016-12-31 22.25 $8.56 2.60
2016-09-30 22.97 $8.59 2.67
2016-06-30 23.68 $8.41 2.82
2016-03-31 19.76 $8.17 2.42
2015-12-31 21.30 $7.81 2.73
2015-09-30 20.56 $7.60 2.70
2015-06-30 21.78 $7.60 2.87
2015-03-31 22.41 $7.68 2.92
2014-12-31 19.89 $7.71 2.58
2014-09-30 18.72 $7.63 2.45
2014-06-30 18.62 $7.60 2.45
2014-03-31 19.97 $7.44 2.68
2013-12-31 18.89 $7.40 2.55
2013-09-30 17.58 $7.14 2.46
2013-06-30 17.00 $6.97 2.44
2013-03-31 17.37 $7.00 2.48
2012-12-31 14.96 $7.25 2.06
2012-09-30 14.69 $6.99 2.10
2012-06-30 13.48 $7.39 1.82
2012-03-31 13.14 $7.62 1.73
2011-12-31 12.43 $7.71 1.61
2011-09-30 10.05 $8.17 1.23
2011-06-30 11.59 $8.03 1.44
2011-03-31 11.31 $8.08 1.40
2010-12-31 9.65 $8.07 1.20
2010-09-30 9.37 $8.40 1.12
2010-06-30 7.69 $8.13 0.95
2010-03-31 9.16 $7.63 1.20
2009-12-31 9.62 $7.20 1.34
2009-09-30 8.67 $7.05 1.23
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $142.241B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94